GT Biopharma Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 18, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Market Cap	19	20	7	11	29	98
Market Cap Growth	164.80%	194.21%	-35.48%	-63.56%	-70.36%	159.99%
Enterprise Value	9.61	13.24	2.86	-3.35	12.65	65.84
Last Close Price	0.51	0.79	3.05	7.65	26.57	91.50
PB Ratio	2.39	3.46	-4.08	1.41	2.47	4.46
P/TBV Ratio	0.85	0.75	-	1.38	2.40	3.92
EV/EBITDA Ratio	-	-	-	0.25	-	-
EV/EBIT Ratio	-	-	-	0.25	-	-
EV/FCF Ratio	-	-	-	0.38	-	-
Debt / Equity Ratio	-	0	0	0	0.01	0.00
Net Debt / Equity Ratio	-1.18	-1.18	2.36	-1.86	-1.39	-1.46
Net Debt / EBITDA Ratio	0.67	0.55	0.28	1.02	0.77	0.56
Net Debt / FCF Ratio	0.68	0.53	0.31	1.57	1.07	2.05
Quick Ratio	3.69	2.94	0.67	2.11	3.34	3.12
Current Ratio	3.97	3.25	0.69	2.12	3.35	3.14
Return on Equity (ROE)	-565.21%	-1377.75%	-453.47%	-79.09%	-124.15%	1542.28%
Return on Assets (ROA)	-147.36%	-201.36%	-156.63%	-88.03%	-86.93%	-304.07%
Return on Invested Capital (ROIC)	-2702.74%	-2440.47%	-1792.14%	-1852.11%	-9007.20%	-427.84%
Return on Capital Employed (ROCE)	-199.57%	-603.45%	-494.80%	-140.87%	-126.12%	1529.04%
Buyback Yield / Dilution	-484.42%	-190.57%	-40.79%	-26.87%	-13.19%	-542.06%
Total Shareholder Return	-484.42%	-190.57%	-40.79%	-26.87%	-13.19%	-542.06%

SEC Filings: 10-K · 10-Q